Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Acute HF Patients Live Longer When Seen by Specialists

Michael O'Riordan

August 09, 2024

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Daily News

More Mortality Reduction Signals With Implantable Hemodynamic Monitors in HFrEF: Meta-analysis

L.A. McKeown

February 12, 2024

News Daily News

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

Michael O'Riordan

September 18, 2023

News Daily News

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Michael O'Riordan

June 23, 2023

News Daily News

Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data

Michael O'Riordan

March 29, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

US Dobutamine Shortage a ‘Huge Problem’—What’s the Solution?

Shelley Wood

July 15, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Michael O'Riordan

April 15, 2021

News Daily News

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

Shelley Wood

May 09, 2019

News Daily News

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Michael O'Riordan

January 02, 2018

Advertisement

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Acute HF Patients Live Longer When Seen by Specialists

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

More Mortality Reduction Signals With Implantable Hemodynamic Monitors in HFrEF: Meta-analysis

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

US Dobutamine Shortage a ‘Huge Problem’—What’s the Solution?

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content